Table 3.

Clinical Models to Assess MLV Vaccine Candidate Efficacy.

MLV Vx Candidate	N	Challenge Route	Challenge Dose	Challenge Strain	Challenge Timepoint (dpv)	Observation Period (dpc)	Readouts
BA71ΔCD2 [92,93]	6	IM	103 HAD50 (20 LD50)	BA71	24	24	CS, T, V, NS
	6						CS, T, V
	6
	6
	6		104 HAD50 (20 LD50)	E75
	6
	6
	6		20 LD50	Georgia/07			CST, T, V, NS
	6
	6	tick	12 ticks/pig	RSA/11/2017	16	20	CS
	6	IM	102 HAU	Ken06.Bus	21
	6
	4		102 HAU		42	28	CS, T, V
SY18ΔI226R [98]	5	IM	104 TCID50	SY18	21	28	CS, T, V, OS, RS, HP, T qPCR
	5		102.5 TCID50
ASFV-G-Δ9GL/UK [99]	9	IM	103 HAD50	Georgia/07	28	21	CS, T, V
	10
	15
	5				7
	5				14
	5				21
ASFV-SY-18-ΔCD2v/UK [100]	5	IM	104 TCID50	ASFV-SY18	28	21	CS.T. TGP, TqPCR
ASFV-G-ΔMGF [101]	10	IM	103 HAD50	Georgia/07	28	21	CS, T. V
	10
ASFV-G-ΔI177L/ΔLVR [102]	5	IM	103 HAD50	Georgia/07	28	21	CS, T. V
	5
HLJ/18-7GD [103]	4	IM	200 PLD50	HLJ/18	21	21	CS, TqPCR
	4
	5				28
	5				70
	5				14
	5	oral			21

Readouts: CS = clinical signs, T = temperature, V = viremia, NS = nasal swab, OS = oral swab, RS = rectal swab, HP = histopathology, TqPCR = tissue PCR, TGP = tissue gross pathology.